Opioid prescription is on the increase

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse with health insurance from a large statutory provider is published in the latest issue of Deutsches Ärzteblatt International.

Behind this study lies the intention to improve pain treatment with opioids, particularly for patients with cancer. Prescribing too little results in inadequate alleviation of pain, while supplying too much entails the risk of addiction, especially in patients who do not have cancer.

The proportion of persons in the sample who received opioids increased between 2000 and 2010, and so did the number of daily doses per recipient. 3.7 million inhabitants of Germany received opioids in 2010, a million more than in 2000. The frequency of prescription of WHO step 3 opioids increased—most of all in noncancer patients, in spite of the lack of good evidence for this indication.

The study points to inappropriate provision: Despite the increase in opioid prescription, it cannot be concluded that are receiving in adequate amounts.

More information: Dtsch Arztebl Int 2013; 110(4): 45-51

Provided by Deutsches Aerzteblatt International

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.